Canopy Growth Corp WEED

Morningstar Rating

Company Report

Having Burned Through the Constellation Investment, Canopy Growth Is at Risk for More Dilution

Canopy Growth grows and sells cannabis products primarily in Canada, which accounts for roughly 50% of sales. Unfortunately, the Canadian market is overloaded with too many licensed producers, leading to tough price competition and a stubbornly robust illicit market, so Canopy has yet to reach profitability. We forecast low-single-digit growth over the next decade for the Canadian market, driven by the conversion of illicit consumers into the legal market.

Price vs Fair Value

WEED is trading at a 16% premium.
Price
CAD 6.21
Fair Value
CAD 47.00
Uncertainty
Extreme
1-Star Price
CAD 37.00
5-Star Price
CAD 1.20
Economic Moat
Yql
Capital Allocation
Lfjk

Bulls Say, Bears Say

Bulls

Canopy USA allows Canopy Growth to strengthen its competitive position even before US federal legalization allows it to directly enter.

Bears

While Canopy waits for US federal legalization to enter the THC market there, US multistate operators continue to grow bigger and become more competitive.

News

Trading Information

Previous Close Price
Day Range
52-Week Range
Bid/Ask
/
Market Cap
Volume/Avg
/

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1.75
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield

Company Profile

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include skincare products under Martha Stewart CBD and Storz & Bickel vaporizers. Canopy growth merged its US assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
1,029

Competitors

Valuation

Metric
WEED
CURLF
ACB
Price/Earnings (Normalized)
13.93
Price/Book Value
0.942.270.78
Price/Sales
1.751.641.34
Price/Cash Flow
44.28
Price/Earnings
WEED
CURLF
ACB

Financial Strength

Metric
WEED
CURLF
ACB
Quick Ratio
1.480.401.25
Current Ratio
2.151.093.76
Interest Coverage
−5.32−0.22−3.16
Quick Ratio
WEED
CURLF
ACB

Profitability

Metric
WEED
CURLF
ACB
Return on Assets (Normalized)
−15.23%−2.85%0.97%
Return on Equity (Normalized)
−37.47%−8.42%1.54%
Return on Invested Capital (Normalized)
−11.79%−0.13%0.91%
Return on Assets
WEED
CURLF
ACB

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
YxrgwpqtcZwk$88.3 Bil
Merck KGaA ADR
MKKGY
ZcxfnbvjpHglwdry$78.0 Bil
Haleon PLC ADR
HLN
MnfhwggfZcs$48.4 Bil
Viatris Inc
VTRS
ZhkznynpXfxz$13.8 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
SzjkrmbnJjxn$13.5 Bil
Catalent Inc
CTLT
RrklyrcdCwbbvb$10.9 Bil
Prestige Consumer Healthcare Inc
PBH
CwhvdpkdJvxzwtl$3.5 Bil
Perrigo Co PLC
PRGO
MrtxwkpJjpz$3.5 Bil
Green Thumb Industries Inc
GTBIF
RgmdvhprmYfg$2.5 Bil
Curaleaf Holdings Inc
CURLF
YrnwvxvzGbyzd$2.3 Bil

Sponsor Center